---
figid: PMC4761092__BPH-173-856-g010
figtitle: Scheme of the role of (+)‐naltrexone and (+)‐naloxone in TLR4 signalling
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Danio rerio
pmcid: PMC4761092
filename: BPH-173-856-g010.jpg
figlink: /pmc/articles/PMC4761092/figure/bph13394-fig-0010/
number: F10
caption: Scheme of the role of (+)‐naltrexone and (+)‐naloxone in TLR4 signalling.
  TLR4 signals via two main pathways involving the adaptor proteins, MyD88 or TRIF.
  MyD88‐dependent signalling induces activation of the transcription factors NF‐κB
  and AP‐1. TRIF‐dependent signalling causes the activation of NF‐κB and IRF3. NF‐κB
  and AP‐1 activation results in the induction of pro‐inflammatory cytokines. IRF3
  activation induces type I IFN production. IFN‐β activates the type I IFN receptor
  and its corresponding JAK‐STAT pathway in an autocrine and paracrine fashion, leading
  to the production of inducible NOS. It should be pointed out that these TLR4 signalling
  pathways have been well characterized (Takeuchi and Akira, 2010). (+)‐Naltrexone
  and (+)‐naloxone bind to the MD2 and biasedly inhibit the TLR4‐TRIF‐IRF3 signalling
  pathway (thin line). The unaffected signalling pathway is represented by a thick
  line.
papertitle: Pharmacological characterization of the opioid inactive isomers (+)‐naltrexone
  and (+)‐naloxone as antagonists of toll‐like receptor 4.
reftext: X Wang, et al. Br J Pharmacol. 2016 Mar;173(5):856-869.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.956482
figid_alias: PMC4761092__F10
figtype: Figure
redirect_from: /figures/PMC4761092__F10
ndex: edad4f9b-deb0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4761092__BPH-173-856-g010.html
  '@type': Dataset
  description: Scheme of the role of (+)‐naltrexone and (+)‐naloxone in TLR4 signalling.
    TLR4 signals via two main pathways involving the adaptor proteins, MyD88 or TRIF.
    MyD88‐dependent signalling induces activation of the transcription factors NF‐κB
    and AP‐1. TRIF‐dependent signalling causes the activation of NF‐κB and IRF3. NF‐κB
    and AP‐1 activation results in the induction of pro‐inflammatory cytokines. IRF3
    activation induces type I IFN production. IFN‐β activates the type I IFN receptor
    and its corresponding JAK‐STAT pathway in an autocrine and paracrine fashion,
    leading to the production of inducible NOS. It should be pointed out that these
    TLR4 signalling pathways have been well characterized (Takeuchi and Akira, 2010).
    (+)‐Naltrexone and (+)‐naloxone bind to the MD2 and biasedly inhibit the TLR4‐TRIF‐IRF3
    signalling pathway (thin line). The unaffected signalling pathway is represented
    by a thick line.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IFNB1
  - TLR4
  - IFNR
  - IFNAR2
  - MYD88
  - TRIM69
  - TICAM1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - IRF3
  - NFKB1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - IL16
  - TNF
  - NOS2
  - ISYNA1
  - Ifnb1
  - Tlr4
  - Myd88
  - Rnf138
  - Trim69
  - Ticam1
  - Ticam2
  - Irf3
  - Nfkb1
  - Jun
  - Il16
  - Tnf
  - Nos2
  - myd88
  - ticam1
  - stat1b
  - stat4
  - irf3
  - il16
  - tnfb
  - nos1
  - (+)-Naloxone
  - (+)-Naltrexone
---
